Optimizing the Use of Molecular Testing in Lung Cancer: An AJMC Stakeholder Interchange Report

July 14, 2020

With the advent of next-generation sequencing (NGS), molecular testing has substantially advanced the treatment paradigm and improved overall outcomes for oncogene-driven non-small cell lung cancer (NSCLC). However, universal molecular testing of the population of patients who may benefit has been limited by issues related to insurance coverage, long turnaround times with commercial platforms, and lack of adequate tissue for analysis. A recent stakeholder interchange from

With the advent of next-generation sequencing (NGS), molecular testing has substantially advanced the treatment paradigm and improved overall outcomes for oncogene-driven non-small cell lung cancer (NSCLC). However, universal molecular testing of the population of patients who may benefit has been limited by issues related to insurance coverage, long turnaround times with commercial platforms, and lack of adequate tissue for analysis. A recent stakeholder interchange from The American Journal of Managed Care® included practitioners from the academic and community oncology settings to discuss the role of molecular testing for treatment of NSCLC, evidence to support molecular testing for oncogenic drivers, practice-level challenges related to molecular testing, and opportunities to improve the utility of molecular testing. Joshua Bauml, MD of the Perelman School of Medicine at the University of Pennsylvania in Philadelphia, Pennsylvania, led this discussion.